North America Musculoskeletal Msk Disease Management Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) : %
Período de pronóstico |
1 –2030 |
Tamaño del mercado (año base) |
|
Tamaño del mercado (año de pronóstico) |
USD 21,318.48 |
Tasa de crecimiento anual compuesta (CAGR) |
|
Jugadoras de los principales mercados |
North America Musculoskeletal (MSK) Disease Management Market, By Type (Digital Biofeedback System, Musculoskeletal-Focused Digital Apps (MDAs), Solutions, and Others), Technology (Precision Motion Technology, Computer Vision Technology, and Other Technologies), Integration Type (Phone, Tablet, Computer, and Others), Modality (Virtual Therapy, In-Person Therapy, Customized/Personalized Therapy, and Others), Application (Pre-Surgery Application and Post-Surgery Application), Patient Population (Pediatrics, Adults, and Geriatrics), End User (Hospitals & Clinics, Nursing Homes, Health Centers, Rehabilitation Centres, Virtual/Home Health Care Settings, and Others) - Industry Trends and Forecast to 2030.
North America Musculoskeletal (MSK) Disease Management Market Analysis and Insights
The increasing demand of technological advancements in the diagnosis of MSK diseases, rising awareness about MSK diseases, growing prevalence of RA, and increasing cases of bone fractures. These are the factors which are expected to drive the market growth.
North America musculoskeletal (MSK) disease management market is expected to grow in the forecast year due to the rise in market players and the availability of advanced monitoring devices. Along with this, manufacturers are engaged in the developmental activity for launching novel devices and efficient and accurate products in the market. The increasing development in the field of advanced healthcare techniques is further boosting market growth. However, difficulties such as the stringent regulations for the production and commercialization of products are expected to restrain market growth in the forecast period.
Increasing healthcare expenditure on advancement and development is expected to provide opportunities for market growth. However, the high cost of disease management devices is expected to pose a challenge to market growth. Various companies are taking initiatives that gradually lead to market growth.
Data Bridge Market Research analyzes that the North America musculoskeletal (MSK) disease management market is expected to reach a value of USD 21,318.48 million by 2030, at a CAGR of 23.0% during the forecast period of 2023-2030.
Report Metric |
Details |
Forecast Period |
2023 to 2030 |
Base Year |
2022 |
Historic Year |
2021 (Customizable to 2015 – 2020) |
Quantitative Units |
Revenue in Million, Volumes in Units, and Pricing in USD |
Segments Covered |
Type (Digital Biofeedback System, Musculoskeletal-Focused Digital Apps (MDAs), Solutions, and Others), Technology (Precision Motion Technology, Computer Vision Technology, and Other Technologies), Integration Type (Phone, Tablet, Computer, and Others), Modality (Virtual Therapy, In-Person Therapy, Customized/Personalized Therapy, and Others), Application (Pre-Surgery Application and Post-Surgery Application), Patient Population (Pediatrics, Adults, and Geriatrics), End User (Hospitals & Clinics, Nursing Homes, Health Centers, Rehabilitation Centres, Virtual/Home Health Care Settings, and Others) |
Countries Covered |
U.S., Canada, and Mexico |
Market Players Covered |
RecoveryOne (U.S), Kiio (U.S), Omada Health Inc. (U.S), DarioHealth Corp. (U.S), IncludeHealth (U.S), kaia health (U.S), IMC. (U.S), Wellness Coaches USA LLC (U.S), Sparta Science(U.S), Movement RX(U.S), Phzio (Canada), Airrosti Rehab Center LLC (U.S), SimpleTherapy Inc. (U.S), Hinge Health, Inc. (U.S), Sword Health Inc. (U.S), SPRITE HEALTH (U.S), and Limber Health Inc. (U.S) among others. |
Market Definition
Musculoskeletal (MSK) disease or impairments comprise more than 150 different diseases or conditions which internally affect the human system and are characterized by deficiencies in the muscles, bones, joints, and adjacent connective tissues, which lead to lifelong hindrances in functioning and participation. The conditions are characterized by pain, limited gait movement, and dexterity, thereby reducing people’s aptitude to work and participate in society.
The management of MSK diseases involves consultation with a physician, integrated with telemedicine, which is the use of digital biofeedback systems (DBSs), musculoskeletal-focused digital apps (MDAs), and therapies. Physical activity and weight management programs are also important self-management activities for persons with arthritis. Virtual therapy or remote consultation entails a holistic approach with the implementation of video conference and phone consultations in MSK practice.
North America Musculoskeletal (MSK) Disease Management Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Technological advances in the diagnosis of musculoskeletal disorders (MSDS)
Musculoskeletal disorders (MSDs) are injuries and disorders that affect the movement of the human body in the musculoskeletal (MSK) system, such as muscles, ligaments, nerves, tendons, cartilage, and discs. Some of the more common MSK conditions are myasthenia gravis, Osteoarthritis (OA), gout, Rheumatoid Arthritis (RA), back pain, osteoporosis, and Systemic Lupus Erythematosus (SLE). MSK pain has various causes. For example, muscle tissue can be damaged by wear and tear during daily activities. The strain on human body parts due to sprains, car accidents, falls, jerky movements, fractures, dislocations, and direct muscle blows also cause MSK pain.
For instance,
- In June 2018, Konica Minolta Healthcare Americas, Inc. launched the SONIMAGE MX1 portable ultrasound system developed for MSK and orthopedic practices, interventional guidelines, and ambulatory care centers. The SONIMAGE MX1 is built with the power and portability that doctors need to safely and effectively diagnose at the point of care. In March 2018, Philips presented a new 3-tesla MRI scanner called Ingenia Elition 3.0T at ECR 2018 in Vienna.
Thus, innovative steps and technological advancements by market players to improve the quality and efficiency of therapeutic research for MSDs are expected to drive market growth in the coming years.
- Rising awareness about musculoskeletal disorders (MSDS)
MSK diseases are associated with sports, occupational accidents, and aging-related dysfunctions. Some of the most common MSK conditions include back pain, RA, OA, osteoporosis, septic arthritis, gout, myasthenia gravis, SLE, and others. MSK disease management involves the diagnosis and treatment of all acute and chronic diseases that affect the MSK system, that is, muscles, bones, tendons, joints, and ligaments, as well as the treatment of non-surgical injuries of the MSK system.
According to reports published by the Bone and Joint Diseases Associations, the three most common MSK conditions are arthritis, back pain, and trauma.
Henceforth, the rising awareness about MSDs is positively associated with market growth in the coming years.
Restraint
- High cost of diagnosis and treatment of orthopedic diseases
Chronic orthopedic diseases such as arthritis and bursitis affect the MSK system- most often the bones or joints. They can cause pain and dysfunction, making normal daily activities difficult. These conditions are different from orthopedic injuries, such as a dislocated shoulder or broken bone, which are often caused by sudden trauma. Unlike accidental or traumatic orthopedic injuries, chronic conditions are usually progressive, starting slowly and worsening or developing over time. They may be genetic or age-related, or they may be caused by overuse.
Some orthopedic conditions are treatable, and some cannot be cured at this time but can be treated to reduce pain and improve quality of life. Accurate diagnosis and targeted treatment can help reduce problems even in progressive conditions without treatment. Treatment recommendations depend on the type and severity of your condition. Treatments range from RICE (Rest, Ice, Compression, and Elevation) to major surgery.
For instance,
- Full genome-genome comparisons
- Rapid assessment of polymorphic genetic variations
- Complete construction of orthologous and paralogous groups of genes
- Structure determination of large macromolecular assemblies/complexes
- Dynamical simulation of realistic oligomer systems
All these diagnostic, as well as therapeutic procedures, involve high costs. Thus, the high cost of diagnosis and treatment of orthopedic disease is expected to restrain the market growth.
Opportunity
- Strategic Initiatives by Market Players
The rise in musculoskeletal (MSK) diseases increases the need for strategic business ideas. It includes partnership, business expansion, collaboration, and other developments. In North America MSK disease management, many health agencies and market players entail initiatives that are designed to deliver returns on investment to the customers. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.
For instance -
- In March 2021, SpineZone declared an investment of USD 12.00 million in series a funding to integrate virtual and in-person (telemedicine) MSK care. The investment made is expected to expand the product and business footprint across North America and Europe with new funds.
- In September 2021, IncludeHealth launched the MSK operating system for virtual physical therapy. The MSK operating system provides an integrated virtual and in-person care telehealth experience. The launch was a result of the collaboration of IncludeHealth with Google and ProMedica Health Systems. The launch resulted in the expansion of the product portfolio and a rise in sales.
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may be expected to as an opportunity that is expected to drive the market growth.
Challenge
- Challenges faced by physicians while treating athletes with musculoskeletal (MSK) diseases
Although primary prevention mainly involves coaches and trainers, secondary and tertiary prevention of sport-related injuries, the reduction of injuries as well as their consequences to allowing effective sport participation, are the main challenges for healthcare professionals who treat athletes suffering from MSK diseases. Several unmet needs are required to be addressed, such as heterogeneous epidemiological data reporting sport-related MSK injury.
Various challenges of implementing next-generation sequencing in the clinical laboratory are as follows-
- The challenge faced in improving the prevention and management of Rheumatic and Musculoskeletal Diseases (RMDs) is peripheral nerve repair which is a major challenge in clinical practice
- The special issue by the Italian Society for Unified and Interdisciplinary Management of Musculoskeletal Pain and Algodystrophy (Società Italiana per la Gestione Unificata e Interdisciplinare del Dolore muscolo-scheletrico e dell’Algodistrofia, SI-GUIDA) provided an overview of current epidemiological data, diagnostic challenges, and rationale of therapeutic strategies in the field of sport-related MSK diseases from the point of view of the three specialists most involved in the treatment of MSK pain, including the orthopedist, the rheumatologist, and the physiatrist.
MSK pain is a broad term for multiple conditions with different trajectories but collated together. They represent a substantial burden on physicians, patients (athletes), and the healthcare system. It is a challenging condition for both patients and physicians. Many adults have experienced one or more episodes of MSK pain at some time in their lives, regardless of age, gender, or economic status. In addition, the challenges faced by the physicians would result in less supply and distribution of digital (telehealth) products and less use of therapies. Therefore, the challenges faced by clinicians while treating athletes with MSK diseases are expected to challenge the market growth.
Recent Developments
- In January 2021, DarioHealth Corp. acquired AI-enabled MSK assessment company Physimax. The acquisition resulted in the addition of AI solutions and investments in DarioHealth Corp. MSK care portfolio.
- In January 2021, IncludeHealth formed a partnership with Google and ProMedica for the launch of the MSK operating system. The partnership and the product launch would propel the next generation of telemedicine and remote care. It is also expected to cause a rise in product revenue and expansion of business with existing customers.
North America Musculoskeletal (MSK) Disease Management Market Scope
North America musculoskeletal (MSK) disease management market is segmented into seven segments which are type, technology, integration type, modality, application, patient population, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Digital Biofeedback System
- Musculoskeletal-Focused Digital Apps (MDAS)
- Solutions
- Others
On the basis of type, the North America musculoskeletal (MSK) disease management market is segmented into digital biofeedback system, musculoskeletal-focused digital apps (MDAs), solutions, and others.
Technology
- Precision Motion Technology
- Computer Vision Technology
- Other Technologies
On the basis of technology, the North America musculoskeletal (MSK) disease management market is segmented into precision motion technology, computer vision technology, and other technologies.
Integration Type
- Phone
- Tablet
- Computer
- Others
On the basis of integration type, the North America musculoskeletal (MSK) disease management market is segmented into phone, tablet, computer, and others.
Modality
- Virtual Therapy
- In-Person Therapy
- Customized/ Personalized Therapy
- Others
On the basis of modality, the North America musculoskeletal (MSK) disease management market is segmented into virtual therapy, in-person therapy, customized/personalized therapy, and others.
Application
- Pre-Surgery Application
- Post-Surgery Application
On the basis of application, the North America musculoskeletal (MSK) disease management market is segmented into pre-surgery application and post-surgery application.
Patient Population
- Pediatrics
- Adults
- Geriatrics
On the basis of patient population, the North America musculoskeletal (MSK) disease management market is segmented into pediatrics, adults, and geriatrics.
End User
- Hospitals & Clinics
- Nursing Homes
- Health Centers
- Rehabilitation Centers
- Virtual/Home Health Care Settings
- Others
On the basis of end-user, the North America musculoskeletal (MSK) disease management market is segmented into hospitals & clinics, nursing homes, health centers, rehabilitation centers, virtual/home health care settings, and others.
North America Musculoskeletal (MSK) Disease Management Market Regional Analysis/Insights
North America musculoskeletal (MSK) disease management market is segmented into seven notable segments, which are type, technology, integration type, modality, application, patient population, and end user.
The countries covered in this market report are U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America musculoskeletal (MSK) disease management market due to the rise in technological advancement in musculoskeletal (MSK) disease management products.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Musculoskeletal (MSK) Disease Management Market Share Analysis
North America musculoskeletal (MSK) disease management competitive market landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the North America remote patient monitoring and care market are RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc., Sword Health, Inc., SPRITE HEALTH, and Limber Health, Inc. among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE SEGMENT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 THE CATEGORY VS TIME GRID
2.13 SECONDARY SOURCES
2.14 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCE
4.3 KEY STRATEGIC INITIATIVES
4.4 EMERGING TREND ANALYSIS OF DIGITAL REHABILITATION AND DIGITAL PHYSIOTHERAPY IN THE NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET
4.4.1 DIGITAL REHABILITATION
4.4.2 DIGITAL PHYSIOTHERAPY
5 EPIDEMIOLOGY
5.1 U.S.
5.2 CANADA
5.3 MEXICO
6 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 TECHNOLOGICAL ADVANCES IN THE DIAGNOSIS OF MUSCULOSKELETAL DISORDERS (MSDS)
7.1.2 RISING AWARENESS ABOUT MUSCULOSKELETAL DISORDERS (MSDS)
7.1.3 GROWING PREVALENCE OF RHEUMATOID ARTHRITIS (RA)
7.1.4 INCREASING CASES OF BONE FRACTURES
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSIS AND TREATMENT OF ORTHOPEDIC DISEASES
7.2.2 RISE IN USE OF HEAVY-DUTY DRUGS IN TREATING MUSCULOSKELETAL (MSK) PAIN
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.2 USE OF TELEMEDICINE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.3.3 INCREASED USE OF MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.3.4 USE OF HOME HEALTHCARE FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.4 CHALLENGES
7.4.1 CHALLENGES FACED BY PHYSICIANS WHILE TREATING ATHLETES WITH MUSCULOSKELETAL (MSK) DISEASES
7.4.2 STRICT REGULATORY GUIDELINES FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
8 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIGITAL BIOFEEDBACK SYSTEM
8.3 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
8.3.1 IOS-SYSTEMS
8.3.2 ANDROID-SYSTEMS
8.3.3 OTHER SYSTEMS
8.4 SOLUTIONS
8.4.1 DIRECT SUPPORT
8.4.1.1 MULTIMODAL PAIN THERAPY
8.4.1.2 ONSITE PERSONALIZED THERAPY
8.4.1.3 SOLUTIONS TO REDUCE INJURIES
8.4.1.4 MIND-BODY CONNECTION IMPROVEMENT
8.4.1.5 EARLY PREVENTION AND INTERVENTION
8.4.1.6 PREVENTION, RECOVERY AND EDUCATION
8.4.1.7 PERSONALIZED PAIN RECOVERY
8.4.1.8 SENSOR-GUIDED EXERCISE THERAPY
8.4.1.9 TRAINING OF EDUCATION SKILLS
8.4.1.10 SELF-TRACKING OF PAIN EPISODES
8.4.1.11 RELAXATION TECHNIQUES
8.4.1.12 POST-OPERATIVE PAIN TRACKING
8.4.1.12.1 REAL-TIME MONITORING
8.4.1.12.2 SYMPTOM MANAGEMENT
8.4.1.13 OTHERS
8.4.2 PROGRESS TRACKING
8.4.3 OTHERS
8.5 OTHERS
9 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 PRECISION MOTION TECHNOLOGY
9.3 COMPUTER MOTION TECHNOLOGY
9.4 OTHER TECHNOLOGIES
10 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE
10.1 OVERVIEW
10.2 PHONE
10.2.1 DIGITAL BIOFEEDBACK SYSTEM
10.2.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.2.3 THERAPIES
10.2.4 OTHERS
10.3 TABLET
10.3.1 DIGITAL BIOFEEDBACK SYSTEM
10.3.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.3.3 THERAPIES
10.3.4 OTHERS
10.4 COMPUTER
10.4.1 DIGITAL BIOFEEDBACK SYSTEM
10.4.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.4.3 THERAPIES
10.4.4 OTHERS
10.5 OTHERS
11 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY
11.1 OVERVIEW
11.2 VIRTUAL THERAPY
11.2.1 INTERNET BASED
11.2.2 TELEPHONE BASED
11.2.3 MOBILE PHONE APPLICATION
11.2.4 INTERNET BASED WITH TELEPHONE SUPPORT
11.2.5 INTERACTIVE VOICE RESPONSE
11.2.6 VIDEO TELECONFERENCING
11.2.7 MOBILE PHONE APPLICATION WITH TELEPHONE SUPPORT
11.2.8 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT
11.2.9 INTERNET BASED WITH VIDEO CONFERENCING
11.2.10 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT AND INTERNET BASED
11.2.11 OTHERS
11.3 IN-PERSON THERAPY
11.4 CUSTOMIZED/ PERSONALIZED THERAPY
11.5 OTHERS
12 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 PRE-SURGERY APPLICATION
12.2.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY
12.2.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY
12.2.3 LATERAL LUMBAR INTERBODY FUSION SURGERY
12.2.4 INTERNET BASED WITH TELEPHONE SUPPORT
12.2.5 MINIMALLY INVASIVE SPINE SURGERY
12.2.6 MOTION PRESERVING SPINE SURGERY
12.2.7 POSTERIOR CERVICAL FUSION SURGERY
12.2.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY
12.2.9 SACROILIAC JOINT FUSION SURGERY
12.2.10 SCOLIOSIS CORRECTION SURGERY
12.2.11 VERTEBRAL AUGMENTATION SURGERY
12.2.12 FRACTURE FIXATION SURGERY
12.2.13 HIP SURGERY
12.2.13.1 TOTAL HIP REPLACEMENT
12.2.13.2 PARTIAL HIP REPLACEMENT
12.2.13.3 HIP RESURFACING
12.2.13.4 OTHERS
12.2.14 KNEE SURGERY
12.2.14.1 TOTAL KNEE REPLACEMENT
12.2.14.2 PARTIAL KNEE REPLACEMENT
12.2.14.3 MISS FUSION
12.2.14.4 OTHERS
12.3 POST-SURGERY APPLICATION
12.3.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY
12.3.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY
12.3.3 LATERAL LUMBAR INTERBODY FUSION SURGERY
12.3.4 INTERNET BASED WITH TELEPHONE SUPPORT
12.3.5 MINIMALLY INVASIVE SPINE SURGERY
12.3.6 MOTION PRESERVING SPINE SURGERY
12.3.7 POSTERIOR CERVICAL FUSION SURGERY
12.3.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY
12.3.9 SACROILIAC JOINT FUSION SURGERY
12.3.10 SCOLIOSIS CORRECTION SURGERY
12.3.11 VERTEBRAL AUGMENTATION SURGERY
12.3.12 FRACTURE FIXATION SURGERY
12.3.13 HIP SURGERY
12.3.13.1 TOTAL HIP REPLACEMENT
12.3.13.2 PARTIAL HIP REPLACEMENT
12.3.13.3 HIP RESURFACING
12.3.13.4 OTHERS
12.3.14 KNEE SURGERY
12.3.14.1 TOTAL KNEE REPLACEMENT
12.3.14.2 PARTIAL KNEE REPLACEMENT
12.3.14.3 MISS FUSION
12.3.14.4 OTHERS
13 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION
13.1 OVERVIEW
13.2 PEDIATRICS
13.2.1 MALE
13.2.2 FEMALE
13.3 ADULTS
13.3.1 MALE
13.3.2 FEMALE
13.4 GERIATRIC
13.4.1 MALE
13.4.2 FEMALE
14 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS & CLINICS
14.2.1 MULTIPLE
14.2.2 PHYSICAL THERAPIST
14.2.3 NURSE
14.2.4 HEALTH COACH
14.2.5 OTHERS
14.3 NURSING HOMES
14.3.1 MULTIPLE
14.3.2 PHYSICAL THERAPIST
14.3.3 NURSE
14.3.4 HEALTH COACH
14.3.5 OTHERS
14.4 HEALTH CENTERS
14.4.1 MULTIPLE
14.4.2 PHYSICAL THERAPIST
14.4.3 NURSE
14.4.4 HEALTH COACH
14.4.5 OTHERS
14.5 REHABILITATION CENTERS
14.5.1 MULTIPLE
14.5.2 PHYSICAL THERAPIST
14.5.3 NURSE
14.5.4 HEALTH COACH
14.5.5 OTHERS
14.6 VIRTUAL/HOME HEALTH CARE SETTINGS
14.6.1 MULTIPLE
14.6.2 PHYSICAL THERAPIST
14.6.3 NURSE
14.6.4 HEALTH COACH
14.6.5 OTHERS
14.7 OTHERS
15 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION
15.1 OVERVIEW
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 HINGE HEALTH, INC
18.1.1 COMPANY SNAPSHOT
18.1.2 PRODUCT PORTFOLIO
18.1.3 RECENT DEVELOPMENTS
18.2 SWORD HEALTH, INC
18.2.1 COMPANY SNAPSHOT
18.2.2 PRODUCT PORTFOLIO
18.2.3 RECENT DEVELOPMENT
18.3 OMADA HEALTHA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 PRODUCT PORTFOLIO
18.3.3 RECENT DEVELOPMENT
18.4 KAIA HEALTH
18.4.1 COMPANY SNAPSHOT
18.4.2 PRODUCT PORTFOLIO
18.4.3 RECENT DEVELOPMENTS
18.5 WELLNESS COACHES USA, LLC.
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENT
18.6 AIRROSTI REHAB CENTER, LLC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 DARIOHEALTH CORP. (2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 INCLUDEHEALTH
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 IMC
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 KIIO
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 LIMBER HEALTH, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 MOVEMENT RX
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 PHZIO
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 RECOVERYONE
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 SPARTA SCIENCE
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 SPRITE HEALTH
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 SIMPLETHERAPY, INC.
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tablas
TABLE 1 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 31 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 32 U.S. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 33 U.S. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 34 U.S. MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 35 U.S. SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 36 U.S. DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 37 U.S. POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 38 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 39 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 40 U.S. PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 41 U.S. TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 42 U.S. COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 43 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 44 U.S. VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 45 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 46 U.S. PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 47 U.S. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 48 U.S. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 U.S. POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 50 U.S. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 51 U.S. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 52 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 53 U.S. PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 54 U.S. ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 55 U.S. GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 56 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 57 U.S. HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 58 U.S. NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 59 U.S. HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 60 U.S. REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 62 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 63 CANADA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 64 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 CANADA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 66 CANADA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 67 CANADA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 69 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 70 CANADA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 71 CANADA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 72 CANADA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 73 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 74 CANADA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 75 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 CANADA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 CANADA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 CANADA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 CANADA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 CANADA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 CANADA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 82 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 83 CANADA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 84 CANADA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 85 CANADA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 86 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 87 CANADA HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 88 CANADA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 89 CANADA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 90 CANADA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 91 CANADA VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 92 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 93 MEXICO DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 94 MEXICO DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 95 MEXICO MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 96 MEXICO SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 97 MEXICO DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 98 MEXICO POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 100 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 101 MEXICO PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 102 MEXICO TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 103 MEXICO COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 104 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 105 MEXICO VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 106 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 MEXICO PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 MEXICO HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 MEXICO KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 110 MEXICO POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 111 MEXICO HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 112 MEXICO KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 113 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 114 MEXICO PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 115 MEXICO ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 116 MEXICO GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 117 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 118 MEXICO HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 119 MEXICO NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 120 MEXICO HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 121 MEXICO REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 122 MEXICO VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
Lista de figuras
FIGURE 1 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: GEOGRAPHIC SCOPE
FIGURE 3 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DATA TRIANGULATION
FIGURE 4 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT
FIGURE 5 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BOTTOM-UP APPROACH
FIGURE 6 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: TOP-DOWN APPROACH
FIGURE 7 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: INTERVIEWS BY REGION AND DESIGNATION
FIGURE 8 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: APPLICATION COVERAGE GRID
FIGURE 11 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: THE CATEGORY VS TIME GRID
FIGURE 12 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET SEGMENTATION
FIGURE 13 RISE IN AWARENESS ABOUT MUSCULOSKELETAL (MSK) DISEASES, GROWING PREVALENCE OF RHEUMATOID ARTHRITIS, TECHNOLOGICAL ADVANCEMENTS IN MUSCULOSKELETAL (MSK) DISEASES, AND STRATEGIC INITIATIVES BY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MARKET GROWTH FOR NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN 2023 & 2030
FIGURE 15 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET : EPIDEMIOLOGY
FIGURE 16 PREVALENCE AND INCIDENCE OF RHEUMATOID ARTHRITIS
FIGURE 17 PREVALENCE AND INCIDENCE OF OSTEOARTHRITIS
FIGURE 18 PREVALENCE AND INCIDENCE OF OSTEOPOROSIS
FIGURE 19 PREVALENCE AND INCIDENCE OF PSORIATIC ARTHRITIS
FIGURE 20 PREVALENCE AND INCIDENCE OF ANKYLOSING SPONDYLITIS
FIGURE 21 INCIDENSE OF FIBROMYALGIA
FIGURE 22 PREVALENCE AND INCIDENCE OF TENDINITIS AND CARPEL TUNNEL SYNDROME
FIGURE 23 PREVALENCE AND INCIDENCE OF BONE FRACTURES
FIGURE 24 PREVALENCE AND INCIDENCE OF OSTEOMALACIA AND OSTEOPENIA
FIGURE 25 PREVALENCE AND INCIDENCE OF GOUT
FIGURE 26 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA MUSCULOSKETAL (MSK) DISEASE MANAGEMENT MARKET
FIGURE 27 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2022
FIGURE 28 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 29 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 30 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2022
FIGURE 32 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 33 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 34 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 35 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2022
FIGURE 36 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2023-2030 (USD MILLION)
FIGURE 37 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, CAGR (2023-2030)
FIGURE 38 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2022
FIGURE 40 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2023-2030 (USD MILLION)
FIGURE 41 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, CAGR (2023-2030)
FIGURE 42 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 43 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2022
FIGURE 44 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 45 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 46 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 47 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2022
FIGURE 48 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2023-2030 (USD MILLION)
FIGURE 49 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, CAGR (2023-2030)
FIGURE 50 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, LIFELINE CURVE
FIGURE 51 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2022
FIGURE 52 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 53 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 54 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 55 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022)
FIGURE 56 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022)
FIGURE 57 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 58 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 59 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030)
FIGURE 60 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.